Stroke · 2014 · 68 citations · 53 references
PharmacyPharmacoeconomicsCost-effectiveness AnalysisHealth Technology AssessmentPharmacoeconomic ModelingAcute Ischemic StrokeCost-effectiveness ComparisonCost-effectiveness ModelingHealthcare Cost AnalysisPharmacoeconomic EvaluationStrokeAcute Ischemic Stroke TreatmentCost-effectivenessDirect CostsIncremental Cost EstimationLifetime Cost AnalysisLifetime Healthcare Cost EstimationLong-term Cost-effectiveness ModelingWholesale Acquisition Cost
BACKGROUND AND PURPOSE: Despite the availability of results from multiple newer clinical trials and changing healthcare costs, the cost-effectiveness of recombinant tissue-type plasminogen activator (r-tPA) for treatment of acute ischemic stroke within 0 to 3 hours of symptom onset was last evaluated in 1998 for the United States Using current evidence, we evaluate the long-term cost-effectiveness of r-tPA administered 0 to 3 hours after acute ischemic stroke onset versus no r-tPA. METHODS: A disease-based decision model to project lifetime outcomes of patients after acute ischemic stroke by r-tPA treatment status from the US payer perspective was developed. Model inputs were derived from a recent meta-analysis of r-tPA trials, cohort studies, and health state preference studies. Cost data, inflated to 2013 dollars, were based on drug wholesale acquisition cost and the literature. To compare r-tPA to no r-tPA, we calculated incremental total direct costs, incremental quality-adjusted life years, and incremental cost-effectiveness ratios. We performed 1-way and probabilistic sensitivity analyses to evaluate uncertainty in the results. RESULTS: r-tPA resulted in a gain of 0.39 quality-adjusted life years (95% confidence range, 0.16-0.66) on average per patient and a lifetime cost-saving of $25,000 (95% confidence range, -$42,500 to -$11,000) compared with no r-tPA. In probabilistic sensitivity analyses, r-tPA was dominant compared with no r-tPA in ≈100% of simulations. The model was sensitive to inputs for r-tPA efficacy, healthcare costs for disabled patients, mortality rates for disabled and nondisabled patients, and quality of life estimates. CONCLUSIONS: Our analysis supports earlier economic evaluations that r-tPA is a cost-effective method to treat stroke. Appropriate use of r-tPA should be prioritized nationally.
53
Heart Disease and Stroke Statistics—2012 Update
Véronique L. Roger, Alan S. Go, Donald M. Lloyd‐Jones et al. · Circulation · 2011 · 7.2K citations · Full text
Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke
Werner Hacke, Markku Kaste, Erich Bluhmki et al. · New England Journal of Medicine · 2008 · 6.6K citations · Full text
Heart Disease and Stroke Statistics—2010 Update
Donald M. Lloyd‐Jones, Robert J. Adams, Todd M. Brown et al. · Circulation · 2009 · 5.6K citations